While fibroblast growth factor (FGF) 1 is expressed in multiple tissues, only adipose-derived and brain FGF1 have been implicated in the regulation of metabolism. Adipose FGF1 production is upregulated in response to dietary stress and is essential for adipose tissue plasticity in these conditions. Similarly, in the brain, FGF1 secretion into the ventricular space and the adjacent parenchyma is increased after a hypercaloric challenge induced by either feeding or glucose infusion. Potent anorexigenic properties have been ascribed to both peripheral and centrally injected FGF1. The ability of recombinant FGF1 and variants with reduced mitogenicity to lower glucose, suppress adipose lipolysis and promote insulin sensitization elevates their potential as candidates in the treatment of type 2 diabetes mellitus and associated comorbidities. Here, we provide an overview of the known metabolic functions of endogenous FGF1 and discuss its therapeutic potential, distinguishing between peripherally or centrally administered FGF1. Gasser et al. provide a concise overview of the known metabolic functions of endogenous FGF1 and discuss its therapeutic potential after peripheral or central administration.

中文翻译：

---

代谢信使：成纤维细胞生长因子 1

虽然成纤维细胞生长因子 (FGF) 1 在多种组织中表达，但只有脂肪来源和脑 FGF1 与代谢调节有关。脂肪 FGF1 的产生会因饮食压力而上调，并且对于这些条件下的脂肪组织可塑性至关重要。类似地，在大脑中，在喂食或葡萄糖输注引起的高热量挑战后，FGF1 分泌到脑室空间和邻近的实质中会增加。外周和中央注射的 FGF1 都具有强大的厌食特性。重组 FGF1 和具有降低促有丝分裂性的变体降低葡萄糖、抑制脂肪脂肪分解和促进胰岛素致敏的能力提高了它们作为治疗 2 型糖尿病和相关合并症的候选药物的潜力。这里，我们概述了内源性 FGF1 的已知代谢功能，并讨论了其治疗潜力，区分外周或中央管理的 FGF1。加塞尔等。简要概述内源性 FGF1 的已知代谢功能，并讨论其在外周或中枢给药后的治疗潜力。